RBD-1016, a GalNAc-siRNA therapy effective in hepatitis B models
June 23, 2023
At the ongoing European Association for the Study of the Liver meeting, researchers from Suzhou Ribo Life Science Co. Ltd. presented preclinical data on RBD-1016 in two models of chronic hepatitis B virus (HBV) infection.